BioNTech (NASDAQ:BNTX) Price Target Cut to $122.00 by Analysts at BMO Capital Markets

BioNTech (NASDAQ:BNTX) had its price target trimmed by BMO Capital Markets from $123.00 to $122.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other analysts have also issued reports on BNTX. HC Wainwright restated a buy rating and issued a $107.00 price target on shares of BioNTech in a research note on Wednesday, April 17th. The Goldman Sachs Group dropped their target price on shares of BioNTech from $113.00 to $100.00 and set a neutral rating for the company in a research report on Wednesday, February 28th. Canaccord Genuity Group reaffirmed a buy rating and set a $171.00 price target on shares of BioNTech in a research report on Thursday, March 21st. JPMorgan Chase & Co. lowered their price objective on BioNTech from $99.00 to $90.00 and set an underweight rating for the company in a report on Friday, March 22nd. Finally, UBS Group cut their price objective on BioNTech from $110.00 to $101.00 and set a neutral rating on the stock in a research note on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, BioNTech presently has an average rating of Hold and an average price target of $118.27.

BioNTech Stock Down 2.6 %

Shares of NASDAQ BNTX opened at $90.88 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. BioNTech has a 1 year low of $85.21 and a 1 year high of $125.83. The stock’s 50-day simple moving average is $90.53 and its 200-day simple moving average is $95.99. The firm has a market cap of $21.60 billion, a price-to-earnings ratio of 22.06 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a net margin of 24.26% and a return on equity of 4.60%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. As a group, equities analysts anticipate that BioNTech will post -1.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. CWM LLC lifted its stake in BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after buying an additional 217 shares during the last quarter. GAMMA Investing LLC boosted its stake in BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares during the period. Frazier Financial Advisors LLC bought a new position in BioNTech in the 4th quarter worth about $30,000. Covestor Ltd acquired a new stake in shares of BioNTech in the third quarter valued at approximately $32,000. Finally, First Horizon Advisors Inc. bought a new stake in shares of BioNTech during the fourth quarter valued at approximately $38,000. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.